SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Monday
Stocks in focus: SpaceX jumps after 3 launches; CL Workshop plans $200M ATM; Qualcomm files share offering; Pasqal names IR chief; Neurosense warned.
Stocks · News reference
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases,
NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(2.10). This is a 43.24 percent increase over losses of $(3.70) per share from the same period last year.